LON:HEMO Hemogenyx Pharmaceuticals Interim Earnings Report GBX 731 +31.00 (+4.43%) As of 03:19 AM Eastern ProfileEarnings History Hemogenyx Pharmaceuticals EPS ResultsActual EPS-GBX 101.70Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHemogenyx Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHemogenyx Pharmaceuticals Announcement DetailsQuarterInterimDate9/28/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Hemogenyx Pharmaceuticals Earnings HeadlinesHemogenyx Pharmaceuticals Plc veröffentlicht Ergebnisse für das Halbjahr zum 30. Juni 2026September 29, 2026 | de.marketscreener.comDHemogenyx Pharmaceuticals Plc Reports Earnings Results for the Half Year Ended June 30, 2026September 28, 2026 | marketscreener.comMMy next big call (under $1)Bitcoin is trading near $80,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new money has to flow into a single asset. Not impossible. Now ask what it takes to move a coin with a $40 million market cap. Not a trillion dollars. A fraction of a percent of one. That's the entire reason my team stopped hunting for the next Bitcoin years ago. I put together a short presentation walking through where we're looking instead, and why the largest percentage moves in this market stopped coming from the coins everyone recognizes. | Crypto 101 Media (Ad)Hemogenyx Advances HG-CT-1 AML Trial as First-Half Loss Reaches £6.56 MillionSeptember 28, 2026 | uk.finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Half-year Financial ReportSeptember 28, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals (LON:HEMO) Releases Quarterly Earnings ResultsSeptember 28, 2026 | americanbankingnews.comSee More Hemogenyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email. Email Address About Hemogenyx PharmaceuticalsHemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.View Hemogenyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
